DE | EN
|
A A+
Search
BlueSky
Youtube
Instagram
Facebook
Linkedin
News Medical University of Graz

JACI-D-23-00956-Figure 4

Your Diagram TitleDirected or undirected cell depletion, function or proliferation inhibition → MMF (mycophenolate mofetil): 3Anti-inflammatory drugs → Anti-IL-(interleukin-)12/-23/-IL-17/-18-directed therapies: 3Directed or undirected cell depletion, function or proliferation inhibition → Glucocorticosteroids: 2Directed or undirected cell depletion, function or proliferation inhibition → Rituximab: 2Checkpoint / Treg augmentation → Abatacept, belatacept: 2Checkpoint / Treg augmentation → Rapamycin: 2Directed signaling pathway inhibition → Rapamycin: 2Directed signaling pathway inhibition → Ruxolitinib, baricitinib, tofacitinib: 2Anti-inflammatory drugs → Glucocorticosteroids: 2TCR-signalosome insufficiency → LAT: 1TCR-signalosome insufficiency → SLP76: 1V(D)J-recombination insufficiency → RAG1,2: 1V(D)J-recombination insufficiency → DCLRE1C: 1V(D)J-recombination insufficiency → PRKCD: 1AIRE-expression insufficiency → PRKCD: 1V(D)J-recombination insufficiency → NHEJ1: 1V(D)J-recombination insufficiency → LIG4: 1Purine metabolism insufficiency → ADA: 1CD40:CD40L-signaling insufficiency → CD40LG: 1T:B-cell co-signaling insufficiency → CD40LG: 1ICOS:ICOSL-signaling insufficiency → ICOS: 1T:B-cell co-signaling insufficiency → ICOS: 1TCR-complex insufficiency → CD3G: 1TCR-signalosome insufficiency → ZAP70: 1TCR-signalosome insufficiency → ZAP70/HM-GOF: 1Transcription factor insufficiency → IKZF2: 1Actin-cytoskeleton insufficiency → DOCK8: 1Hippo-signaling insufficiency → STK4: 1TCR-complex insufficiency → TRAC: 1TCR-signalosome insufficiency → LCK: 1TCR-signalosome insufficiency → ITK: 1CBM-signalosome insufficiency → MALT1: 1CBM-signalosome insufficiency → CARD11: 1NFKB1-signaling imbalance → IKBKB-LOF: 1NFKB1-signaling imbalance → IKBKB-GOF: 1NFKB2-signaling imbalance → CHUK: 1AIRE-expression insufficiency → CHUK: 1NFKB2-signaling imbalance → MAP3K14: 1AIRE-expression insufficiency → MAP3K14: 1NFKB2-signaling imbalance → RELB: 1AIRE-expression insufficiency → RELB: 1Actin-cytoskeleton insufficiency → MSN: 1Transferrin uptake insufficiency → TFRC: 1TCR- and BCR-signalosome insufficiency → SASH3: 1Actin-cytoskeleton insufficiency → WAS: 1Actin-cytoskeleton insufficiency → WIPF1: 1Actin-cytoskeleton insufficiency → ARPCB1: 1DNA-damage sensing insufficiency → ATM: 1DNA-methylation insufficiency → DNMT3B: 1DNA-replication insufficiency → POLE2: 1Transcription factor insufficiency → Del22q11.2, TBX1: 1Transcription factor insufficiency → FOXN1: 1Contiguous gene syndrome → Del11q23del: 1Mitochondrial RNA-metabolism insufficiency → RMRP: 1Replication fork DNA-reannealing insufficiency → SMARCAL1: 1JAK/STAT/SOCS-signaling imbalance → STAT3-DN: 1Glycosylation insufficiency → PGM3: 1Folate cycle insufficiency → MTHFD1: 1Store-operated calcium-entry insufficiency → ORAI1: 1Store-operated calcium-entry insufficiency → STIM1: 1Purine metabolism insufficiency → PNP: 1TLR7-ligand availability imbalance → PNP: 1IL-2-signalling imbalance → STAT5B: 1Histone-methylation imbalance → KMT2D: 1Histone-methylation imbalance → KDM6A: 1PIP3-signalling imbalance → PIK3CD: 1PIP3-signalling imbalance → PIK3R1: 1PIP3-signalling imbalance → PTEN: 1B-cell co-receptor-signaling insufficiency → CD19: 1B-cell co-receptor-signaling insufficiency → CD81: 1BAFF/APRIL/BLYS:TACI-signaling insufficiency → TNFRSF13B: 1B-cell co-signaling insufficiency → TNFRSF13B: 1TWEAK:TWEAKR-signaling insufficiency → TNFSF12: 1T:B-cell co-signaling insufficiency → TNFSF12: 1NFKB1-signaling imbalance → NFKB1: 1NFKB2-signaling imbalance → NFKB2: 1AIRE-expression insufficiency → NFKB2: 1Transcription factor insufficiency → IKZF1: 1Transcriptional co-factor insufficiency → IRF2BP2: 1Actin-cytoskeleton insufficiency → ARHGEF1: 1Actin-cytoskeleton insufficiency → RAC2: 1PIP3-signalling imbalance → PIK3CG: 1Class-switch-recombination and somatic hypermutation insufficiency → AICDA: 1Class-switch-recombination and somatic hypermutation insufficiency → UNG: 1Class-switch-recombination and somatic hypermutation insufficiency → CTNNBL1: 1BAFF/APRIL/BLYS:TACI-signaling insufficiency → TNFSF13: 1B-cell co-signaling insufficiency → TNFSF13: 1CBM-signalosome insufficiency → CARD11-GOF: 1Transcription factor insufficiency → FOXP3: 1IL-2-signalling imbalance → IL2RA,B: 1CTLA4-insufficiency → CTLA4: 1CTLA4-insufficiency → LRBA: 1CTLA4-insufficiency → DEF6: 1JAK/STAT/SOCS-signaling imbalance → STAT3-GOF: 1Transcription factor insufficiency → BACH2: 1AIRE-expression insufficiency → AIRE: 1Ubiquitination-insufficiency → ITCH: 1Protein homeostasis-insufficiency → TPP2: 1JAK/STAT/SOCS-signaling imbalance → JAK1: 1Collagen homeostasis-insufficiency → PEPD: 1JAK/STAT/SOCS-signaling imbalance → SOCS1: 1PDCD1LG1/PDCD1LG2: PDCD1-signaling insufficiency → PDCD1: 1FASL:FAS-signaling insufficiency → FAS, FASL: 1FASL:FAS- and TNF:TNFR-signaling insufficiency → CASP10: 1FASL:FAS-, TNF:TNFR- and RIPK1-signaling insufficiency → CASP8: 1FASL:FAS- and TNF:TNFR-signaling insufficiency → FADD: 1DNA-methylation insufficiency → TET2: 1FASL:FAS-signaling insufficiency → TET2: 1Mitochondrial glucose utilization insufficiency → G6PC3: 1Mitochondrial glucose utilization insufficiency → G6PT1: 1NADPH-oxidase insufficiency → CYBB, CYBA, NCF1, NCF2: 1IL-1-family imbalance → CYBB, CYBA, NCF1, NCF2: 1Complement tagging insufficiency → C1QA, B, C: 1Complement tagging insufficiency → C4A, B: 1Complement tagging insufficiency → C2: 1Complement tagging insufficiency → C3: 1LAT → HCT: 1SLP76 → HCT: 1RAG1,2 → HCT: 1RAG1,2 → GT: 1DCLRE1C → HCT: 1DCLRE1C → GT: 1PRKCD → HCT: 1PRKCD → Directed or undirected cell depletion, function or proliferation inhibition: 1NHEJ1 → HCT: 1LIG4 → HCT: 1ADA → Substrate/enzyme replacement therapy: 1ADA → HCT: 1ADA → GT: 1CD40LG → HCT: 1CD40LG → HCT: 1ICOS → Directed or undirected cell depletion, function or proliferation inhibition: 1ICOS → HCT: 1CD3G → HCT: 1ZAP70 → HCT: 1ZAP70/HM-GOF → HCT: 1IKZF2 → Directed or undirected cell depletion, function or proliferation inhibition: 1IKZF2 → HCT: 1DOCK8 → HCT: 1STK4 → HCT: 1TRAC → HCT: 1LCK → HCT: 1ITK → HCT: 1MALT1 → HCT: 1CARD11 → HCT: 1IKBKB-LOF → HCT: 1IKBKB-GOF → Directed or undirected cell depletion, function or proliferation inhibition: 1CHUK → HCT: 1CHUK → Directed or undirected cell depletion, function or proliferation inhibition: 1MAP3K14 → HCT: 1MAP3K14 → Directed or undirected cell depletion, function or proliferation inhibition: 1RELB → HCT: 1RELB → Directed or undirected cell depletion, function or proliferation inhibition: 1MSN → Directed or undirected cell depletion, function or proliferation inhibition: 1MSN → HCT: 1TFRC → Directed or undirected cell depletion, function or proliferation inhibition: 1TFRC → HCT: 1SASH3 → Directed or undirected cell depletion, function or proliferation inhibition: 1SASH3 → HCT: 1WAS → HCT: 1WAS → GT: 1WIPF1 → HCT: 1ARPCB1 → HCT: 1ATM → Directed or undirected cell depletion, function or proliferation inhibition: 1ATM → HCT: 1DNMT3B → Directed or undirected cell depletion, function or proliferation inhibition: 1DNMT3B → HCT: 1POLE2 → Directed or undirected cell depletion, function or proliferation inhibition: 1Del22q11.2, TBX1 → Thymus transplantation: 1FOXN1 → Thymus transplantation: 1Del11q23del → Directed or undirected cell depletion, function or proliferation inhibition: 1Del11q23del → Thymus transplantation: 1RMRP → Directed or undirected cell depletion, function or proliferation inhibition: 1RMRP → HCT: 1SMARCAL1 → Directed or undirected cell depletion, function or proliferation inhibition: 1SMARCAL1 → HCT: 1STAT3-DN → Anti-inflammatory drugs: 1STAT3-DN → HCT: 1PGM3 → Directed or undirected cell depletion, function or proliferation inhibition: 1PGM3 → HCT: 1MTHFD1 → Substrate/enzyme replacement therapy: 1ORAI1 → HCT: 1STIM1 → HCT: 1PNP → Substrate/enzyme replacement therapy: 1PNP → HCT: 1PNP → GT: 1STAT5B → Directed or undirected cell depletion, function or proliferation inhibition: 1STAT5B → HCT: 1KMT2D → Directed or undirected cell depletion, function or proliferation inhibition: 1KDM6A → Directed or undirected cell depletion, function or proliferation inhibition: 1PIK3CD → Directed signaling pathway inhibition: 1PIK3CD → HCT: 1PIK3R1 → Directed signaling pathway inhibition: 1PIK3R1 → HCT: 1PTEN → Directed signaling pathway inhibition: 1CD19 → Directed or undirected cell depletion, function or proliferation inhibition: 1CD81 → Directed or undirected cell depletion, function or proliferation inhibition: 1TNFRSF13B → Directed or undirected cell depletion, function or proliferation inhibition: 1TNFRSF13B → Directed or undirected cell depletion, function or proliferation inhibition: 1TNFSF12 → Directed or undirected cell depletion, function or proliferation inhibition: 1TNFSF12 → Directed or undirected cell depletion, function or proliferation inhibition: 1NFKB1 → Directed or undirected cell depletion, function or proliferation inhibition: 1NFKB1 → Anti-inflammatory drugs: 1NFKB1 → HCT: 1NFKB2 → HCT: 1NFKB2 → Directed or undirected cell depletion, function or proliferation inhibition: 1IKZF1 → Directed or undirected cell depletion, function or proliferation inhibition: 1IKZF1 → HCT: 1IRF2BP2 → Directed or undirected cell depletion, function or proliferation inhibition: 1IRF2BP2 → Anti-inflammatory drugs: 1ARHGEF1 → Directed or undirected cell depletion, function or proliferation inhibition: 1RAC2 → Directed or undirected cell depletion, function or proliferation inhibition: 1PIK3CG → Directed signaling pathway inhibition: 1PIK3CG → Directed or undirected cell depletion, function or proliferation inhibition: 1AICDA → Directed or undirected cell depletion, function or proliferation inhibition: 1UNG → Directed or undirected cell depletion, function or proliferation inhibition: 1CTNNBL1 → Directed or undirected cell depletion, function or proliferation inhibition: 1TNFSF13 → Directed or undirected cell depletion, function or proliferation inhibition: 1TNFSF13 → Directed or undirected cell depletion, function or proliferation inhibition: 1CARD11-GOF → Directed or undirected cell depletion, function or proliferation inhibition: 1FOXP3 → HCT: 1FOXP3 → Checkpoint / Treg augmentation: 1FOXP3 → Directed or undirected cell depletion, function or proliferation inhibition: 1IL2RA,B → HCT: 1IL2RA,B → Checkpoint / Treg augmentation: 1IL2RA,B → Directed or undirected cell depletion, function or proliferation inhibition: 1CTLA4 → HCT: 1CTLA4 → Checkpoint / Treg augmentation: 1LRBA → HCT: 1LRBA → Checkpoint / Treg augmentation: 1DEF6 → HCT: 1DEF6 → Checkpoint / Treg augmentation: 1STAT3-GOF → Directed signaling pathway inhibition: 1STAT3-GOF → Anti-inflammatory drugs: 1BACH2 → Checkpoint / Treg augmentation: 1BACH2 → Directed or undirected cell depletion, function or proliferation inhibition: 1BACH2 → Anti-inflammatory drugs: 1AIRE → Checkpoint / Treg augmentation: 1AIRE → Directed or undirected cell depletion, function or proliferation inhibition: 1ITCH → Checkpoint / Treg augmentation: 1ITCH → Directed or undirected cell depletion, function or proliferation inhibition: 1TPP2 → Directed or undirected cell depletion, function or proliferation inhibition: 1TPP2 → HCT: 1JAK1 → Directed signaling pathway inhibition: 1JAK1 → Anti-inflammatory drugs: 1PEPD → Directed or undirected cell depletion, function or proliferation inhibition: 1PEPD → Anti-inflammatory drugs: 1SOCS1 → Directed signaling pathway inhibition: 1SOCS1 → Anti-inflammatory drugs: 1PDCD1 → Directed or undirected cell depletion, function or proliferation inhibition: 1FAS, FASL → Directed signaling pathway inhibition: 1CASP10 → Directed signaling pathway inhibition: 1CASP8 → Directed signaling pathway inhibition: 1CASP8 → Directed or undirected cell depletion, function or proliferation inhibition: 1CASP8 → HCT: 1FADD → Directed signaling pathway inhibition: 1FADD → Directed or undirected cell depletion, function or proliferation inhibition: 1FADD → HCT: 1TET2 → Directed or undirected cell depletion, function or proliferation inhibition: 1TET2 → Directed signaling pathway inhibition: 1TET2 → HCT: 1G6PC3 → Directed signaling pathway inhibition: 1G6PT1 → Directed signaling pathway inhibition: 1CYBB, CYBA, NCF1, NCF2 → HCT: 1CYBB, CYBA, NCF1, NCF2 → GT: 1CYBB, CYBA, NCF1, NCF2 → Anti-inflammatory drugs: 1C1QA, B, C → Directed signaling pathway inhibition: 1C1QA, B, C → Directed or undirected cell depletion, function or proliferation inhibition: 1C1QA, B, C → Anti-inflammatory drugs: 1C4A, B → Directed signaling pathway inhibition: 1C4A, B → Directed or undirected cell depletion, function or proliferation inhibition: 1C4A, B → Anti-inflammatory drugs: 1C2 → Directed signaling pathway inhibition: 1C2 → Directed or undirected cell depletion, function or proliferation inhibition: 1C2 → Anti-inflammatory drugs: 1C3 → Directed signaling pathway inhibition: 1C3 → Directed or undirected cell depletion, function or proliferation inhibition: 1C3 → Anti-inflammatory drugs: 1Directed or undirected cell depletion, function or proliferation inhibition → CAAR- (chimeric autoantibody receptor-) T cells: 1Directed or undirected cell depletion, function or proliferation inhibition → Daratumumab: 1Directed or undirected cell depletion, function or proliferation inhibition → Belimumab: 1Directed or undirected cell depletion, function or proliferation inhibition → Epratuzumab: 1Directed or undirected cell depletion, function or proliferation inhibition → Ibrutinib: 1Directed or undirected cell depletion, function or proliferation inhibition → Blinatumomab: 1Directed or undirected cell depletion, function or proliferation inhibition → Inebilizumab: 1Directed or undirected cell depletion, function or proliferation inhibition → Alemtuzumab: 1Directed or undirected cell depletion, function or proliferation inhibition → ATG (anti-thymocyte globulin): 1Directed or undirected cell depletion, function or proliferation inhibition → AZT (azathioprine): 1Directed or undirected cell depletion, function or proliferation inhibition → Vbl (vinblastine): 1Directed or undirected cell depletion, function or proliferation inhibition → CY (cyclophosphamide): 1Directed or undirected cell depletion, function or proliferation inhibition → VP16 (etoposide): 1Directed or undirected cell depletion, function or proliferation inhibition → CyA (cyclosporin A): 1Directed or undirected cell depletion, function or proliferation inhibition → Bortezomib, Carfilzomib: 1Directed or undirected cell depletion, function or proliferation inhibition → Lenalidomid, thalidomide: 1Checkpoint / Treg augmentation → Low-dose aldesleukin: 1Checkpoint / Treg augmentation → CAR-Tregs: 1Directed signaling pathway inhibition → Fostamatinib: 1Directed signaling pathway inhibition → Idelalisib: 1Directed signaling pathway inhibition → Leniosilib: 1Directed signaling pathway inhibition → Hydroxychloroquine: 1Anti-inflammatory drugs → Anakinra: 1Anti-inflammatory drugs → Tocilizumab: 1Anti-inflammatory drugs → Anti-TNF: 1Anti-inflammatory drugs → Anti-IFN: 1Anti-inflammatory drugs → Anifrolumab: 1TCR-signalosome insufficiency: 6LAT: 1SLP76: 1V(D)J-recombination insufficiency: 5RAG1,2: 2DCLRE1C: 2PRKCD: 2AIRE-expression insufficiency: 6NHEJ1: 1LIG4: 1Purine metabolism insufficiency: 2ADA: 3CD40:CD40L-signaling insufficiency: 1CD40LG: 2T:B-cell co-signaling insufficiency: 3ICOS:ICOSL-signaling insufficiency: 1ICOS: 2TCR-complex insufficiency: 2CD3G: 1ZAP70: 1ZAP70/HM-GOF: 1Transcription factor insufficiency: 6IKZF2: 2Actin-cytoskeleton insufficiency: 7DOCK8: 1Hippo-signaling insufficiency: 1STK4: 1TRAC: 1LCK: 1ITK: 1CBM-signalosome insufficiency: 3MALT1: 1CARD11: 1NFKB1-signaling imbalance: 3IKBKB-LOF: 1IKBKB-GOF: 1NFKB2-signaling imbalance: 4CHUK: 2MAP3K14: 2RELB: 2MSN: 2Transferrin uptake insufficiency: 1TFRC: 2TCR- and BCR-signalosome insufficiency: 1SASH3: 2WAS: 2WIPF1: 1ARPCB1: 1DNA-damage sensing insufficiency: 1ATM: 2DNA-methylation insufficiency: 2DNMT3B: 2DNA-replication insufficiency: 1POLE2: 1Del22q11.2, TBX1: 1FOXN1: 1Contiguous gene syndrome: 1Del11q23del: 2Mitochondrial RNA-metabolism insufficiency: 1RMRP: 2Replication fork DNA-reannealing insufficiency: 1SMARCAL1: 2JAK/STAT/SOCS-signaling imbalance: 4STAT3-DN: 2Glycosylation insufficiency: 1PGM3: 2Folate cycle insufficiency: 1MTHFD1: 1Store-operated calcium-entry insufficiency: 2ORAI1: 1STIM1: 1PNP: 3TLR7-ligand availability imbalance: 1IL-2-signalling imbalance: 2STAT5B: 2Histone-methylation imbalance: 2KMT2D: 1KDM6A: 1PIP3-signalling imbalance: 4PIK3CD: 2PIK3R1: 2PTEN: 1B-cell co-receptor-signaling insufficiency: 2CD19: 1CD81: 1BAFF/APRIL/BLYS:TACI-signaling insufficiency: 2TNFRSF13B: 2B-cell co-signaling insufficiency: 2TWEAK:TWEAKR-signaling insufficiency: 1TNFSF12: 2NFKB1: 3NFKB2: 2IKZF1: 2Transcriptional co-factor insufficiency: 1IRF2BP2: 2ARHGEF1: 1RAC2: 1PIK3CG: 2Class-switch-recombination and somatic hypermutation insufficiency: 3AICDA: 1UNG: 1CTNNBL1: 1TNFSF13: 2CARD11-GOF: 1FOXP3: 3IL2RA,B: 3CTLA4-insufficiency: 3CTLA4: 2LRBA: 2DEF6: 2STAT3-GOF: 2BACH2: 3AIRE: 2Ubiquitination-insufficiency: 1ITCH: 2Protein homeostasis-insufficiency: 1TPP2: 2JAK1: 2Collagen homeostasis-insufficiency: 1PEPD: 2SOCS1: 2PDCD1LG1/PDCD1LG2: PDCD1-signaling insufficiency: 1PDCD1: 1FASL:FAS-signaling insufficiency: 2FAS, FASL: 1FASL:FAS- and TNF:TNFR-signaling insufficiency: 2CASP10: 1FASL:FAS-, TNF:TNFR- and RIPK1-signaling insufficiency: 1CASP8: 3FADD: 3TET2: 3Mitochondrial glucose utilization insufficiency: 2G6PC3: 1G6PT1: 1NADPH-oxidase insufficiency: 1CYBB, CYBA, NCF1, NCF2: 3IL-1-family imbalance: 1Complement tagging insufficiency: 4C1QA, B, C: 3C4A, B: 3C2: 3C3: 3HCT: 57GT: 6Directed or undirected cell depletion, function or proliferation inhibition: 54Substrate/enzyme replacement therapy: 3Thymus transplantation: 3Anti-inflammatory drugs: 13Directed signaling pathway inhibition: 18Checkpoint / Treg augmentation: 8Glucocorticosteroids: 4Rituximab: 2CAAR- (chimeric autoantibody receptor-) T cells: 1Daratumumab: 1Belimumab: 1Epratuzumab: 1Ibrutinib: 1Blinatumomab: 1Inebilizumab: 1Alemtuzumab: 1ATG (anti-thymocyte globulin): 1AZT (azathioprine): 1MMF (mycophenolate mofetil): 3Vbl (vinblastine): 1CY (cyclophosphamide): 1VP16 (etoposide): 1CyA (cyclosporin A): 1Bortezomib, Carfilzomib: 1Lenalidomid, thalidomide: 1Abatacept, belatacept: 2Rapamycin: 4Low-dose aldesleukin: 1CAR-Tregs: 1Fostamatinib: 1Idelalisib: 1Leniosilib: 1Ruxolitinib, baricitinib, tofacitinib: 2Hydroxychloroquine: 1Anakinra: 1Tocilizumab: 1Anti-TNF: 1Anti-IL-(interleukin-)12/-23/-IL-17/-18-directed therapies: 3Anti-IFN: 1Anifrolumab: 1TCR-signalosome insufficiencyLATSLP76V(D)J-recombination insufficiencyRAG1,2DCLRE1CPRKCDAIRE-expression insufficiencyNHEJ1LIG4Purine metabolism insufficiencyADACD40:CD40L-signaling insufficiencyCD40LGT:B-cell co-signaling insufficiencyICOS:ICOSL-signaling insufficiencyICOSTCR-complex insufficiencyCD3GZAP70ZAP70/HM-GOFTranscription factor insufficiencyIKZF2Actin-cytoskeleton insufficiencyDOCK8Hippo-signaling insufficiencySTK4TRACLCKITKCBM-signalosome insufficiencyMALT1CARD11NFKB1-signaling imbalanceIKBKB-LOFIKBKB-GOFNFKB2-signaling imbalanceCHUKMAP3K14RELBMSNTransferrin uptake insufficiencyTFRCTCR- and BCR-signalosome insufficiencySASH3WASWIPF1ARPCB1DNA-damage sensing insufficiencyATMDNA-methylation insufficiencyDNMT3BDNA-replication insufficiencyPOLE2Del22q11.2, TBX1FOXN1Contiguous gene syndromeDel11q23delMitochondrial RNA-metabolism insufficiencyRMRPReplication fork DNA-reannealing insufficiencySMARCAL1JAK/STAT/SOCS-signaling imbalanceSTAT3-DNGlycosylation insufficiencyPGM3Folate cycle insufficiencyMTHFD1Store-operated calcium-entry insufficiencyORAI1STIM1PNPTLR7-ligand availability imbalanceIL-2-signalling imbalanceSTAT5BHistone-methylation imbalanceKMT2DKDM6APIP3-signalling imbalancePIK3CDPIK3R1PTENB-cell co-receptor-signaling insufficiencyCD19CD81BAFF/APRIL/BLYS:TACI-signaling insufficiencyTNFRSF13BB-cell co-signaling insufficiencyTWEAK:TWEAKR-signaling insufficiencyTNFSF12NFKB1NFKB2IKZF1Transcriptional co-factor insufficiencyIRF2BP2ARHGEF1RAC2PIK3CGClass-switch-recombination and somatic hypermutation insufficiencyAICDAUNGCTNNBL1TNFSF13CARD11-GOFFOXP3IL2RA,BCTLA4-insufficiencyCTLA4LRBADEF6STAT3-GOFBACH2AIREUbiquitination-insufficiencyITCHProtein homeostasis-insufficiencyTPP2JAK1Collagen homeostasis-insufficiencyPEPDSOCS1PDCD1LG1/PDCD1LG2: PDCD1-signaling insufficiencyPDCD1FASL:FAS-signaling insufficiencyFAS, FASLFASL:FAS- and TNF:TNFR-signaling insufficiencyCASP10FASL:FAS-, TNF:TNFR- and RIPK1-signaling insufficiencyCASP8FADDTET2Mitochondrial glucose utilization insufficiencyG6PC3G6PT1NADPH-oxidase insufficiencyCYBB, CYBA, NCF1, NCF2IL-1-family imbalanceComplement tagging insufficiencyC1QA, B, CC4A, BC2C3HCTGTDirected or undirected cell depletion, function or proliferation inhibitionSubstrate/enzyme replacement therapyThymus transplantationAnti-inflammatory drugsDirected signaling pathway inhibitionCheckpoint / Treg augmentationGlucocorticosteroidsRituximabCAAR- (chimeric autoantibody receptor-) T cellsDaratumumabBelimumabEpratuzumabIbrutinibBlinatumomabInebilizumabAlemtuzumabATG (anti-thymocyte globulin)AZT (azathioprine)MMF (mycophenolate mofetil)Vbl (vinblastine)CY (cyclophosphamide)VP16 (etoposide)CyA (cyclosporin A)Bortezomib, CarfilzomibLenalidomid, thalidomideAbatacept, belataceptRapamycinLow-dose aldesleukinCAR-TregsFostamatinibIdelalisibLeniosilibRuxolitinib, baricitinib, tofacitinibHydroxychloroquineAnakinraTocilizumabAnti-TNFAnti-IL-(interleukin-)12/-23/-IL-17/-18-directed therapiesAnti-IFNAnifrolumab